Matthew Goodchild’s Post

Have you heard of time toxicity as a complication of cancer treatment? Time toxicity is a complication of many healthcare conditions and treatments, including cancer. It represents the time a patient needs to devote to receiving care. If you or a loved one have dealt with the US healthcare system as a patient, you likely know exactly what this means. Time toxicity is not just the time at the doctor's office, it's all the adjacent activities around those visits. And for patients undergoing cancer treatment, those tasks can be monumental. This is why treatments with fixed durations are important. If we can get good disease outcomes with a therapy that has a finite treatment period, that provides huge benefits to our patients; they can reduce their time toxicity as well as drug and cost toxicities. An example of this is mosunetuzumab, a first-in class bispecific antibody that targets CD20. It has a fixed duration treatment option for patients with follicular lymphoma, which is ~6 months if a complete response is achieved and ~12 months for a partial response. Read the JCO article on time toxicity in the comments 👇 --- 📌 Whenever you’re ready to prioritize having a solid oncology clinical knowledgebase for you or your staff, the Enjoy Learning Oncology (ELO) program can help you I’m Kelley 👋 and I help pharmacists learn the complex world of oncology #LearnOncology #Pharmacists #OncologyPharmacists KelleyCPharmD

2024 Healthcare Change Maker: Dr. Joanna Gotfrit https://lnkd.in/gapTHzK9 Canada’s complex drug approval and funding process sometimes leads patients to experience long delays before their oncologists can prescribe the drugs that could change their lives. For Dr. Joanna Gotfrit, a medical oncologist at the The Ottawa Hospital Cancer Centre, the status quo leaves a lot to be desired. “As our population continues to age, I worry about increasing wait lists for care, especially for life-altering diseases such as cancer.” [see the full article for more] #specialtypharmaceuticals #Canada #patients #patientsfirst #healthoutcomes #data #healthcare #pharmaceuticalindustry #outcomes #innovation #access #drug #drugaccess #realworldevidence

🎗Cancer Survivors care 🔺People are living longer after a cancer diagnosis because of advances in early detection and treatment. 🔺Everyone is at risk of developing cancer. 🔺Yet, people with a personal history of cancer are at greater risk than people who have never had cancer. 🔺Medical and public health professionals can help prepare patients for the possible long-term and late effects of cancer and its treatment. 🔺That's where the survivorship care plan comes into play. 🔺Patients should receive survivorship care plans once their cancer treatment comes to a conclusion. 🔺Furthermore, they appoint the healthcare professionals responsible for different aspects of care. 🔺After completing their cancer treatment, many patients don't come back for follow-up care. 🔺This survivorship care plan can facilitate coordination and guidance of care between patients and their medical team, ensuring that patients receive the necessary follow-up treatment. 🔺Some cancer care programs now include plans to improve the standard of care. #healthservices #pharmacy #healthprofessionals #healthcareprofessional #pharmaceuticals #medicalcare #cancertreatment #heathcare #Radiotherapy #medicalequipment #medicaldevices #HealthIT #MedEd #Patient #Physicians #Telemedicine #oncology #cancerawareness #tumor #oncologycare #clinicaleducation #drugs #healthcare

Pharmacists can not only help manage physical toxicities of cancer therapies, they can help develop treatment plans that lower other toxicities, such as time and cost. Having a solid understanding of oncology diseases and treatments allows pharmacists to fully participate in patient care. We support clinicians in developing that baseline knowledge through robust online training programs.

🔍 A single cancer regimen may include up to five or six medicines, sourced from various suppliers. Fragmented procurement and resulting stock-outs lead to treatment with incomplete, and thus substandard, regimens in many LMICs. At NCDconnect, we're addressing this critical issue head-on. Our oncology catalogue is meticulously developed to provide access to complete regimens, following National Comprehensive Cancer Network® (NCCN®) guidelines, for the most common cancers. By consolidating procurement on our digital platform, we empower healthcare providers worldwide to deliver high-quality treatments. With agreements in place with over 10 suppliers - both generics and innovators - we curate direct connections between our customers and the supply source. This approach eliminates price mark-ups and ensures complete access to cancer treatments. 💡 Access to complete and #quality treatments for cancer patients should not be determined by where you live. Join us in our mission to bridge this gap for cancer patients worldwide. https://lnkd.in/et_VjJMj #CancerTreatment #HealthcareEquity #NCDconnect #GlobalHealth #AccessToMedicines #Procurementinnovation

** Oncology Clinical Trials: Driving High Value Service Through a Multiple Site ** As a former COO of a not-for-profit cancer research organisation, I am excited to share an article that highlights the pivotal role we playedin advancing oncology treatments through a multiple site clinical trial operation (MSCTO). Our work span across various locations, including both urban and rural areas, ensuring that we delivered high-value services to patients and sponsors alike. In this article, I delve into the many benefits of a MSCTOs: 1. **Enhancing Patient Access and Diversity**: By reaching both urban and rural populations, we provided more patients the opportunity to participate in cutting-edge trials, leading to comprehensive data for developing effective therapies. 2. **Improving Trial Efficiency and Speed**: Our multi-site approach accelerates patient recruitment and trial completion, which is crucial for timely access to life-saving treatments for the general population. 3. **Ensuring High-Quality Data and Robust Results**: Diverse sites maintain high standards of data collection, a strict adherence to a robust QA system to reduce biases and enhance the reliability of our findings. 4. **Facilitating Comprehensive Patient Care**: Participants receive close monitoring and care, especially beneficial in rural areas where advanced treatments are often limited. 5. **Offering Value to Sponsors**: Our expertise and established networks ensure efficient trial management, high-quality data, and significant return on investment. Check out the full article to learn more about how MSCTOs are transforming cancer research and improving patient outcomes. Read the full article below #Oncology #ClinicalTrials #Innovation #Healthcare #PatientCare #Research #MedicalAdvancements #DiversityInResearch #cancerresearch #cancertreatment

Companion diagnostics (CDx) streamline the treatment process by quickly identifying the most personalized therapy for a patient. CDx is integral in the development of new cancer drugs, thereby improving treatment outcomes and minimizing unnecessary side effects. Recent advancements in companion diagnostics show significant innovation and collaboration among leading companies. Want to know the latest advancements in companion diagnostics regarding cancer treatment? Check out the carousel below! Moreover, the adoption of innovative medical procedures and clinical trials aimed at improving cancer diagnosis is rising. This fosters the development and implementation of companion diagnostics within Latin America.  Accordingly, our analysis predicts that the Latin America companion diagnostics market is set to rise at a CAGR of 12.10% over the forecast period 2022-2028. Interested in knowing the market trends for the companion diagnostics market in other regions? Check out the detailed report here or get a customized one: https://lnkd.in/gqZHry7H . . . Abbott Almac Group ARUP Laboratories Biocartis #companiondiagnostics #cdx #healthcare #diagnostics #cancertreatment #diagnostictests #cancerdiagnosis #interestingfacts #marketgrowth #tritonmarketresearch

Neither physicians nor pharmaceutical companies believed that cancer patients would do this. That they would be able to answer questions related to clinical trial requirements. And would be willing at all. Clinical trials that offer ground-breaking and, possibly, life-saving treatments for patients. “I had a feeling that's not right”, Danielle Ralic, the CEO of Ancora.ai says in the new X-Health.show episode. So at the end of their online clinical trial search questionnaire they asked: Do you want to join clinical trials within the next 6 months? Why are you here? 67% of the platform users said yes. “And the second question about what's the reason for your search today? If I'm honest, I read through them because I wanted to see for myself what the text was before we did our analysis, and definitely had a good cry after. So I thank everyone who completed those fields. It was absolutely eye-opening. People had said, I'm out of approved therapies, I need something, or I'm on my last approved therapy and I'm not sure it's working, so I want to already see what's coming next. I want to contribute to research, so I want to see what's out there, how can I help”. Listen to how the platform aims to connect cancer patients with clinical trials and ease the complicated and frustrating recruitment process for both trial sponsors and patients on Apple Podcasts https://rebrand.ly/af25d6 or Spotify https://rebrand.ly/toh92wn Ancora.ai is a Swiss startup that developed an AI-powered platform where cancer patients and their loved ones, but also oncologists and MDs, can search for available trials in a matter of minutes. #clinicaltrials #clinicaltrial #cancer #cancerresearch #healthcareinnovation #swissstartups #xhealth Buzzsprout

𝐈𝐧𝐬𝐢𝐠𝐡𝐭𝐬 𝐟𝐫𝐨𝐦 #𝐀𝐒𝐂𝐎2024: 𝐓𝐫𝐚𝐧𝐬𝐟𝐨𝐫𝐦𝐢𝐧𝐠 𝐁𝐫𝐞𝐚𝐬𝐭 𝐂𝐚𝐧𝐜𝐞𝐫 𝐂𝐚𝐫𝐞 𝐰𝐢𝐭𝐡 𝐓-𝐃𝐗𝐝 !? The DESTINY-Breast06 trial shows Fam-trastuzumab deruxtecan-nxki (T-DXd) as a possible new standard of care following ≥1 endocrine-based therapy for patients with HER2-low and -ultralow, HR+ metastatic breast cancer. T-DXd shows significant improvement in progression-free survival compared to chemotherapy. Key Highlights from the phase III DB-06 trial: Enhanced Progression-Free Survival: T-DXd extends median progression-free survival to 13.2 months, compared to 8.1 months with chemotherapy in HER2-low patients. Higher Objective Response Rates: T-DXd achieves an ORR of 56.5% in HER2-low (vs 32.3% for chemotherapy) and 61.8% in HER2-ultralow patients (vs 26.3% for chemotherapy). Side Effects: While serious side effects were more common with T-DXd (41% vs. 31% with chemotherapy), they were manageable as patients on T-DXd received treatment for a longer period. Could T-DXd significantly improve the patient journey and become a preferred first-line treatment for HR-positive metastatic breast cancer post-endocrine therapy, offering a promising alternative to traditional chemotherapy? 𝐍𝐨𝐰, 𝐰𝐡𝐚𝐭 𝐝𝐨𝐞𝐬 𝐭𝐡𝐢𝐬 𝐦𝐞𝐚𝐧 𝐟𝐨𝐫 𝐲𝐨𝐮 𝐚𝐧𝐝 𝐡𝐞𝐚𝐥𝐭𝐡𝐜𝐚𝐫𝐞 𝐭𝐨𝐦𝐨𝐫𝐫𝐨𝐰? The best place for us to have this chat is at Healthcare Innovators Connect, an invite-only meeting to dive deeper into these groundbreaking developments! Our scientific team initiates conversations that drive healthcare evolution. We will give you this: exclusive discussions, access to industry leaders, and collaboration opportunities. Drop me a message for an invite to our next session. All sessions will stay invite-only. PS: If you've read this far, we know you're motivated to make impactful changes with us. #HealthcareInnovation #DrivePatientCare #HealthcareInnovatorsConnect #IPTLfromSingapore

The latest editorial in our open-access journal from Richard Sullivan covers key issues such as price and affordability of cancer medicines. It looks at global policies in this area and asks what can be done to improve the situation? #educationsaveslives https://lnkd.in/e6-rCmqg